Summary
Three platinum derivatives, cis-dichlorodiammine platinum (II), (DDP), cis-trans-dichlorodihydroxy-bis-(isopropylamine)platinum (IV) (CHIP) and cis-dichloro-bis-cyclopropylamine platinum (II) (CP), have been prepared with a gamma-emitting platinum label. The distribution of these complexes was studied in male rats.
The results are presented as fractions of the administered radiolabel per gram of tissue and per total organ. Accumulation in the liver was highest initially following CP and lowest after DDP, but by 14 days the levels in kidney and liver were highest with CP. The concentration in the skin was relatively high after all the compounds, but was the most conspicuous after DDP at the early times. In general, patterns of distribution between the other organs were similar with DDP and CP.
CHIP, however, exhibited a different pattern of distribution. Over the first 24 h the level of platinum in most tissues declined more rapidly than after either of the other two compounds but the residual label persisted for a longer period. In the kidney there appeared to be a secondary uptake of labelled material, presumably from other tissues. The level present at 14 days after CHIP was also significantly higher in a number of other organs than after the other two drugs. The increase in label in the spleen at the later times may be due to the removal of circulating damaged cells and consistent with the higher levels of residual platinum in the blood. There was also a higher level of residual platinum in the blood especially after IV administration of the labelled agent.
The results show that CHIP was cleared at a faster rate from blood and kidney than the other two complexes, results which closely resembled clinical findings with these three agents, to be published elsewhere.
The greater retention time of label after CHIP also suggests that longer-term toxicity may follow its repeated administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bannister SJ, Chang Y, Stevenson LR, Repta AJ (1978) Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammine platinum (II). Clin Chem 24:877–880
Creaven PJ, Mihich E (1981) In: Mihich E (ed) New leads in cancer therapeutics. G.K. Hall, Boston, pp 21–23
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlorodiammine platinum (NSC 119875): Therapeutic index in an animal model. Cancer 39:1357–1361
DeConti RC, Toftness BR, Lange RC, Creasey WA (1973) Clinical and pharmacological studies with cis-diammine dichloroplatinum (II). Cancer Res 33:1310–1315
De Simone PA, Yancey RS, Coupal JJ, Butts JD, Hoeschele JD (1979) Effect of forced diuresis on the distribution and excretion (via urine and bile) of 195m-platinum when given as 195m-platinum cis-dichlorodiammine platinum (II). Cancer Treat Rep 63:951–960
Hoeschele JD, Johnson NP, Rahn RO, Brown DH (1978) Comparative studies of 195m Pt-labelled dichlorodiammine platinum (II), DDP in the rat with emphasis on the localisation in DNA. Biochemie 60:1054
Hoeschele JD, Butler TA, Roberts JA (1980) Correlations of physico-chemical and biological properties with in vivo biodistribution data from platinum-195m-labelled chloroammine platinum (II) complexes. In: Martell AE (ed) Inorganic chemistry in biology and medicine. American Chemical Society, pp 181–208 (ACS Symposium Series No 140, 1980)
Kidani Y, Inagaki K, Saito R, Tsukagoshi S (1977) Synthesis and anti-tumour activities of platinum (II) complexes of 1,2-diamminocyclohexane isomers and their related derivatives. J Clin Haematol Oncol 7:197–209
Lange RC, Spencer RP, Harder HC (1972) Synthesis and distribution of a radiolabelled antitumour agent: cis-dichlorodiamine platinum (II). J Nucl Med 13:320–328
Lange RC, Spencer RP, Harder HC (1973) The antitumour agent cisPt(NH3)2,Cl2; distribution studies and dose calculations for 193mPt and 195mPt. J Nucl Med 14:191–195
Litterst CL, Cram TE, Dedrick RJ, Leroy AR, Guarino AM (1976) Distribution and disposition of platinum following administration of cis-diamminodichloro platinum (II) (NSC 119875) to dogs. Cancer Res 36:2340–2344
Litterst CL, Torres IJ, Guarino AM (1977) Plasma levels and organ distribution of Platinum in the rat, dog and dogfish shark following single intravenous administration of cis-dichlorodiammine platinum (II). J Clin Haematol Oncol 7:169–179
Patton TF, Himelstein KJ, Belt R, Bannister SJ, Sternson LA, Repta AJ (1978) Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammine platinum (II) in man. Cancer Treat Rep 62:1359–1362
Pera MF Jr, Harder HC (1977) Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23:1245–1249
Ridgeway H, Speer RJ, Hall LM, Stewart DP, Hewman AD, Gennings A, Zepta A, Brown V, Hill JM (1978) Tissue distribution and excretion of sulfato trans(-)-1,2-diamino cyclohexane platinum (II) Pt-195 in rat. J Clin Haematol Oncol 8:1–10
Rozencweig M, van Hoff DD, Slavik M, Muggia FM (1977) cis-Diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med 80:803–811
Sharma HL, Smith AG (1981) The short lived radioisotope production programme at Manchester. J Radioanalyt Chem 64:249–255
Shepherd DR, Kusnierozyk H, Jones M, Harrap KR (1980) Criteria for the selection of second generation platinum compounds. Br J Cancer 42:668–676
Smith PHS, Taylor DM (1974) Distribution and retention of the antitumour agents 195m-Pt cis-dichlorodiammine platinum (II) in man. J Nucl Med 15:349–351
Speer RJ, Ridgway H, Stewart DP, Hall LM, Zapata A, Hill JM (1977) Sulfato 1,2-diaminocyclohexane platinum (II): A potential new antitumour agent. J Clin Haematol Oncol 7:210–219
Taylor DM (1978) The pharmacokinetics of cis-diamminodichloro-platinum (II) in animals and man: relation to treatment scheduling. Biochimie 60:949–956
Taylor DM, Jones JD, Robinson AB (1973) Metabolism of platinum [14C] ethylenediammine dichloride in the rat. Biochem Pharmacol 22:833–839
Thatcher N, Crowther D, Sharma H, Smith A, Harrison R, Zaki A, McAuliffe CA, Fox BW (1982) Blood clearance of three radioactively labelled Platinum complexes, cis-dichlorodiammine platinum (II), cis-dichlorodihydroxy-bis-(isopropylamine)platinum (IV) and cis-dichloro-bis-cyclopropylamine platinum (II) in patients with malignant disease. Cancer Chemother Pharmacol (in press)
Tobe ML, Khokhar Ar (1977) Structure, activity, reactivity and solubility relationships of platinum diamine complexes. J Clin Haematol Oncol 7:114–137
Ward JM, Grabin ME, LeRoy AF, Young DM (1977) Modification of the renal toxicity of cis-dichlorodiammine platinum (II) with furosemide in male F344 rats. Cancer Treat Rev 61:375–379
Wilkinson R, Cox PJ, Jones M, Harrap KR (1978) Selection of potential second-generation platinum compounds. Biochemie 60:851–857
Wolf W, Manaka RC (1977) Synthesis and distribution of 185m-Pt cis-dichlorodiammine platinum (II). J Clin Haematol Oncol 7:79–95
Wolf W, Manaka RC, Ingalls RB (1973) Radiopharmaceuticals in clinical pharmacology: 195m cis-dichlorodiammine platinum (II) In: Radiopharmaceutical and labelled compounds, vol 2. IAEA, Vienna, pp 205–221
Author information
Authors and Affiliations
Additional information
Present address: Radiochemical Centre, Amersham International
Rights and permissions
About this article
Cite this article
Harrison, R., McAuliffe, C.A., Zaki, A. et al. A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II). Cancer Chemother. Pharmacol. 10, 90–95 (1983). https://doi.org/10.1007/BF00446216
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00446216